iLoF iLoF: AI-augmented photonics to identify and quantify disease biomarkers
- Coordinator
- Ilof - Intelligent Lab on Fiber, Unipessoal Lda, Portugal
- Runs
- 1 August 2023 to 31 July 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190126414
What the project is doing
In the project's own words, from its summary on CORDIS.
iLoF is a digital health company pioneering a breakthrough AI-platform to accelerate the future of personalized drug discovery & development. Through advanced AI & photonics, we collect massive amounts of data to build a digital library of biomarkers & biological profiles, bringing together world-class physicists, biologists, & data scientists to get life-saving personalized treatments to patients faster. Our platform captures label-free patterns in biological liquid samples, to generate specific patient or disease signatures.
The iLoF device generates multiple highly focused, non-destructive laser beams that interrogate the biological sample to obtain a digital signal of its light pattern. That signal is used to detect modifications providing a flexible & agnostic tool that is not limited to a single use or disease. The current project focuses on developing an Alzheimers disease (AD) clinical trial patient screening tool.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ilof - Intelligent Lab on Fiber, Unipessoal Lda | Matosinhos | Portugal | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI